| D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer M Sasako, T Sano, S Yamamoto, Y Kurokawa, A Nashimoto, A Kurita, ... New England Journal of Medicine 359 (5), 453-462, 2008 | 1292 | 2008 |
| Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial K Fujitani, HK Yang, J Mizusawa, YW Kim, M Terashima, SU Han, ... The Lancet Oncology 17 (3), 309-318, 2016 | 702 | 2016 |
| Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria H Katayama, Y Kurokawa, K Nakamura, H Ito, Y Kanemitsu, N Masuda, ... Surgery today 46, 668-685, 2016 | 667 | 2016 |
| Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway R Hamano, H Miyata, M Yamasaki, Y Kurokawa, J Hara, JH Moon, ... Clinical cancer research 17 (9), 3029-3038, 2011 | 294 | 2011 |
| Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer K Fujitani, T Tsujinaka, J Fujita, I Miyashiro, H Imamura, Y Kimura, ... Journal of British Surgery 99 (5), 621-629, 2012 | 206 | 2012 |
| Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study Y Kurokawa, H Takeuchi, Y Doki, S Mine, M Terashima, T Yasuda, ... Annals of surgery 274 (1), 120-127, 2021 | 200 | 2021 |
| A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group … N Hasuike, H Ono, N Boku, J Mizusawa, K Takizawa, H Fukuda, I Oda, ... Gastric Cancer 21, 114-123, 2018 | 191 | 2018 |
| Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial K Shitara, A Takashima, K Fujitani, K Koeda, H Hara, N Nakayama, ... The lancet Gastroenterology & hepatology 2 (4), 277-287, 2017 | 177 | 2017 |
| Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma K Sugimura, H Miyata, K Tanaka, R Hamano, T Takahashi, Y Kurokawa, ... Clinical cancer research 18 (18), 5144-5153, 2012 | 174 | 2012 |
| Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501) T Tsujinaka, M Sasako, S Yamamoto, T Sano, Y Kurokawa, A Nashimoto, ... Annals of Surgical Oncology 14, 355-361, 2007 | 169 | 2007 |
| Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma M Yamasaki, T Makino, T Masuzawa, Y Kurokawa, H Miyata, S Takiguchi, ... British journal of cancer 104 (4), 707-713, 2011 | 163 | 2011 |
| Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the … Japan Clinical Oncology Group (JCOG9502) Kurokawa Y Sasako M msasako@ hyo ... Journal of British Surgery 102 (4), 341-348, 2015 | 161 | 2015 |
| Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) Y Kurokawa, N Sugimoto, H Miwa, M Tsuda, S Nishina, H Okuda, ... British journal of cancer 110 (5), 1163-1168, 2014 | 155 | 2014 |
| miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts K Tanaka, H Miyata, K Sugimura, S Fukuda, T Kanemura, K Yamashita, ... Carcinogenesis 36 (8), 894-903, 2015 | 148 | 2015 |
| InBody 720 as a new method of evaluating visceral obesity H Ogawa, K Fujitani, T Tsujinaka, K Imanishi, H Shirakata, A Kantani, ... Hepato-gastroenterology 58 (105), 42-44, 2011 | 146 | 2011 |
| Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo‐controlled phase 2 study Y Hiura, S Takiguchi, K Yamamoto, T Takahashi, Y Kurokawa, ... Cancer 118 (19), 4785-4794, 2012 | 145 | 2012 |
| Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial Y Kurokawa, Y Doki, J Mizusawa, M Terashima, H Katai, T Yoshikawa, ... The Lancet Gastroenterology & Hepatology 3 (7), 460-468, 2018 | 142 | 2018 |
| High infiltration of tumor‐associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for … K Sugimura, H Miyata, K Tanaka, T Takahashi, Y Kurokawa, M Yamasaki, ... Journal of surgical oncology 111 (6), 752-759, 2015 | 142 | 2015 |
| Molecular-based prediction of early recurrence in hepatocellular carcinoma Y Kurokawa, R Matoba, I Takemasa, H Nagano, K Dono, S Nakamori, ... Journal of hepatology 41 (2), 284-291, 2004 | 135 | 2004 |
| Conventional versus traction-assisted endoscopic submucosal dissection for gastric neoplasms: a multicenter, randomized controlled trial (with video) M Yoshida, K Takizawa, S Suzuki, Y Koike, S Nonaka, Y Yamasaki, ... Gastrointestinal Endoscopy 87 (5), 1231-1240, 2018 | 130 | 2018 |
